Abstract
Recent evidence identified a genetic and functional link between Chk2 kinase and p53 as a candidate genome integrity checkpoint and a tumour suppressor pathway. Here we report that in human cells, Chk2 and p53 form protein–protein complexes whose abundance increased upon DNA damage, and whose formation was abrogated through cancer associated mutations in the FHA domain of Chk2, or mutations in the tetramerization domain of p53. Whereas among Li-Fraumeni syndrome families mutations of Chk2 or p53 occur in a mutually exclusive manner, we document that the colon cancer cell line HCT-15 concomitantly lacks functions of both Chk2 and p53, the latter demonstrated by a non-invasive reporter assay monitoring p53-dependent transactivation in live cells. Despite the preserved ability of common cancer-derived mutant p53 proteins to bind and potentially ‘titrate’ activated Chk2, the integrity of the S phase checkpoint response to ionizing radiation remained largely intact and dependent on Chk2 in cells with wild-type, mutant, or no p53. These results provide new mechanistic insights into the Chk2-p53 interplay, suggest how mutations in Chk2 may abrogate its tumour suppressor function, and indicate that compared with individual defects in either Chk2 or p53, concomitant mutations in both of these cell cycle checkpoint regulators may provide some additional selective advantage to tumour cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmuller L, Deppert W . 1999 Oncogene 18: 7706–7717
Bartek J, Iggo R, Gannon J, Lane DP . 1990 Oncogene 5: 893–899
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA . 1999 Science 286: 2528–2531
Carr AM . 2000 Science 287: 1765–1766
Caspari T . 2000 Curr. Biol. 10: R315–R317
Chehab NH, Malikzay A, Appel M, Halazonetis TD . 2000 Genes Dev. 14: 278–288
Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD . 1999 Proc. Natl. Acad. Sci. USA 96: 13777–13782
Durocher D, Henckel J, Fersht AR, Jackson SP . 1999 Mol. Cell. 4: 387–394
Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J . 2001 Nature 410: 842–847
Giaccia AJ, Kastan MB . 1998 Genes Dev. 12: 2973–2983
Gire V, Wynford-Thomas D . 1998 Mol. Cell. Biol. 18: 1611–1621
Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, Osada H, Fujii Y, Takahashi T . 2000 Cancer Res. 60: 4689–4692
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW . 2000 Science 287: 1824–1827
Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, Kastan MB . 2000 Nature 404: 613–617
Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI, Bartek J . 1997 Genes Dev. 11: 1479–1492
Mailand N, Falck J, Lukas C, Syljuåsen RG, Welcker M, Bartek J, Lukas J . 2000 Science 288: 1425–1429
Matsuoka S, Huang M, Elledge SJ . 1998 Science 282: 1893–1897
Meek DW . 2000 Pathol. Biol. (Paris) 48: 246–254
Melchionna R, Chen X-B, Blasina A, McGowan CH . 2000 Nat. Cell. Biol. 2: 762–765
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr AJ, Kohn KW . 1997 Cancer Res. 57: 4285–4300
Petrini JH . 2000 Nat. Genet. 26: 257–258
Rotman G, Shiloh Y . 1999 Oncogene 18: 6135–6144
Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J . 2000 Mol. Cell. Biol. 20: 3497–3509
Selivanova G, Iotsova V, Kiseleva E, Steinbeck M, Bakalkin G, Grafström RC, Wiman KG . 1996 Nucleic Acids Res. 24: 3560–3567
Shaulian E, Zauberman A, Ginsberg D, Oren M . 1992 Mol. Cell. Biol. 12: 5581–5592
Sherr CJ . 1998 Genes Dev. 12: 2984–2991
Shieh S-Y, Ahn J, Tamai K, Taya Y, Prives C . 2000 Genes Dev. 14: 289–300
Sturzbecher HW, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR . 1992 Oncogene 7: 1513–1523
Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310
Xie G, Habbersett RC, Jia Y, Peterson SR, Lehnert BE, Bradbury EM, D'Anna JA . 1998 Oncogene 16: 721–736
Zhou BB, Elledge SJ . 2000 Nature 408: 433–439
Acknowledgements
We thank S Elledge, G Evan, SI Reed, J Jenkins, P Chumakov and M Oren for providing important reagents, and the Danish Cancer Society, the Human Frontier Science Programme, the European Commission, the Danish Medical Research Council, Swedish Cancer Society, Swedish Medical Research Council and the Danish Cancer Research Fund for grant support. Correspondence and requests for material should be addressed to J Bartek (E-mail: bartek@biobase.dk).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Falck, J., Lukas, C., Protopopova, M. et al. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20, 5503–5510 (2001). https://doi.org/10.1038/sj.onc.1204811
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204811
Keywords
This article is cited by
-
Immunohistochemistry analysis of checkpoint kinase 2 in oral squamous cell carcinoma
Applied Cancer Research (2020)
-
Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients
Breast Cancer Research and Treatment (2018)
-
Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers
Scientific Reports (2016)
-
The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population
Hereditary Cancer in Clinical Practice (2015)
-
MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2
Tumor Biology (2015)